BiotechTube
Aeovian Pharmaceuticals

Aeovian Pharmaceuticals

San Francisco, United States· Est.
aeovian.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $95M

Overview

Aeovian Pharmaceuticals is a private, clinical-stage biotech founded in 2020, pioneering selective mTORC1 inhibition to treat diseases of dysregulated cellular growth. Its lead program, AV078, targets a high-unmet need in TSC-related refractory epilepsy, aiming to overcome the safety limitations of non-selective mTOR inhibitors like everolimus. The company has a broader platform of selective mTORC1 and CD38 inhibitors with potential applications across rare and age-related diseases, backed by an experienced leadership team and venture capital investors.

Rare Genetic DiseasesNeurologyAge-related Diseases

Technology Platform

Proprietary platform for developing highly selective small molecule inhibitors of mTORC1 and CD38 to restore cellular metabolic quality control.

Funding History

3
Total raised:$95M
Series B$55M
Series A$35M
Seed$5M

Opportunities

A successful selective mTORC1 inhibitor for TSC epilepsy could address a significant unmet need and serve as a proof-of-concept for treating other mTORopathies and age-related diseases.
The parallel CD38 inhibitor platform opens a large, adjacent market in aging and metabolic disorders, providing a second major growth vector.

Risk Factors

The lead program faces clinical trial risks, including potential failure to demonstrate superior efficacy or safety over existing mTOR inhibitors.
As a pre-revenue private company, Aeovian is also dependent on raising additional capital to fund operations through key milestones.

Competitive Landscape

Competition includes approved non-selective mTOR inhibitors (everolimus, sirolimus) and generic anti-seizure medications. Other companies are developing next-generation mTOR inhibitors and gene therapies for TSC. In age-related diseases, the CD38 space is competitive with several NAD+ booster programs in development.

More companies in Small Molecule Drugs →More companies in United States →